

4121-135

Section II (Amendments to the Claims)

Please amend claims 1, 11-14 and 17, and add new claims 19-21, as set out in the listing of claims 1-21 below.

1. (Currently Amended) A F_v antibody construct having binding sites for an CD16 receptor and a ~~CD30~~ CD30 surface protein.
2. (Previously presented) The F_v antibody construct according to claim 1, wherein the CD16 receptor is derived from NK cells.
3. (Previously presented) The F_v antibody construct according to claim 1, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
4. (Previously presented) The F_v antibody construct according to claim 1, wherein one binding site is present each.
5. (Previously presented) The F_v antibody construct according to claim 4, encoded by the expression vector pKTD16-30 (DEM 12960).
6. (Previously presented) The F_v antibody construct according to claim 1, wherein two binding sites are present for each.
7. (Previously presented) An expression vector, coding for the F_v antibody construct according to claim 1.
8. (Previously presented) The expression vector according to claim 7, which is pKID16-30 (DSM 12960).
9. (Previously presented) A transformant, containing the expression vector according to claim 7.

4121-135

10. (Previously presented) A method of producing the Fv antibody construct according to claim 1, comprising culturing the transformant according to claim 9 under suitable conditions.
11. (Currently amended) A kit comprising:
- (a) an F_V antibody construct ~~according to the invention~~ having binding sites for an CD16 receptor and a CD30 surface protein
 - and/or
 - (b) an expression vector ~~according to the invention~~ coding for said F_V antibody construct, and
 - (c) ~~common~~ at least one auxiliary substances, ~~such as~~ substance selected from the group consisting of buffers, solvents, carriers, controls and markers,
- wherein one or more representatives of the individual components may be present.
12. (Currently amended) ~~Use of the F_V antibody construct according to claim 1~~ A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_V antibody construct having binding sites for an CD16 receptor and a CD30 surface protein.
13. (Currently amended) Use A method according to claim 12, wherein the cells are tumor cells.
14. (Currently amended) Use A method according to claim 13, wherein the tumor cells are selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
15. (Previously presented) The F_V antibody construct according to claim 2, wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.
16. (Previously presented) An expression vector, coding for the F_V antibody construct according to claim 15.

4121-135

17. (Currently amended) ~~Use of the F_v antibody construct according to claim 15~~ A method for lysis of cells expressing CD30 surface proteins, said method comprising contacting said cells with an F_v antibody construct having binding sites for an CD16 receptor and a CD30 surface protein, wherein the CD16 receptor is derived from NK cells, and wherein the CD30 surface protein is derived from a member selected from the group consisting of: Hodgkin's disease cells or Reed-Sternberg cells.

18. (Previously presented) A transformant, containing the expression vector according to claim 8.

19. (New) The F_v construct of claim 1, wherein said F_v antibody construct comprises elements (a) and (b) joined via a peptide linker:

(a) a V_H domain of an antibody and a V_L domain of an anti-CD30 antibody, the domains being joined by a peptide linker; and

(b) a V_H domain of an anti-CD30 antibody and a V_L domain of an anti-CD16 antibody, the domains joined by a peptide linker.

20. (New) A method of treatment of a tumor comprising the step of administering the F_v antibody construct according to claim 1.

21. (New) The method of claim 20, wherein the treatment comprises the lysis of Hodgkin's disease or Reed-Sternberg cells.